Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum

被引:75
作者
Lanvers, C [1 ]
Pinheiro, JPV [1 ]
Hempel, G [1 ]
Wuerthwein, G [1 ]
Boos, J [1 ]
机构
[1] Univ Munster, Childrens Hosp, Dept Pediat Hematol & Oncol, D-48149 Munich, Germany
关键词
L-asparaginase; acute lymphoblastic leukemia; therapeutic drug monitoring; L-aspartic beta-hydroxamate;
D O I
10.1016/S0003-2697(02)00232-4
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The enzyme L-asparaginase (ASNASE). which hydrolyzes L-asparagine (L-Asn) to ammonia and L-aspartic acid (L-Asp), is commonly used for remission induction in acute lymphoblastic leukemia. To correlate ASNASE activity with L-Asn reduction in human serum, sensitise methods for the determination of ASNASE activity are required. Using L-aspartic beta-hydroxamate (AHA) as substrate we developed a sensitive plate reader-based method for the quantification of ASNASE derived from Eseherichia coli and Erwinia chrysanthemi and of pegylated E coli ASNASE in human serum. ASNASE hydrolyzed AHA to L-Asp and hydroxylamine, which was determined at 710 nm after condensation with 8-hydroxyquinoline and oxidation to indooxine. Measuring the indooxine formation allowed the detection of 2 x 10(-5) U ASNASE in 20 mul serum. Linearity was observed within 2.5-75 and 75-1250 U/L with coefficients of correlation of r(2) > 0.99. The coefficients of variation for intra- and interday variability for the three different ASNASE enzymes were 1.98 to 8.77 and 1.73 to 11.0%. The overall recovery was 101 +/- 9.92%. The coefficient of correlation for dilution linearity was determined Lis r(2) = 0.986 for dilutions up to 1:20. This method combined with sensitive methods for the quantification Of L-Asn will allots bioequivalence studies and individualized therapeutic drug monitoring of different ASNASE preparations. (C) 2002 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:117 / 126
页数:10
相关论文
共 33 条
[1]   Structural basis for the activity and substrate specificity of Erwinia chrysanthemi L-asparaginase [J].
Aghaiypour, K ;
Wlodawer, A ;
Lubkowski, J .
BIOCHEMISTRY, 2001, 40 (19) :5655-5664
[2]   Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia [J].
Ahlke, E ;
NowakGottl, U ;
SchulzeWesthoff, P ;
Werber, G ;
Borste, H ;
Wurthwein, G ;
Jurgens, H ;
Boos, J .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 96 (04) :675-681
[3]  
[Anonymous], BR J HAEMATOL
[4]   COMPARATIVE PHARMACOKINETIC STUDIES OF 3 ASPARAGINASE PREPARATIONS [J].
ASSELIN, BL ;
WHITIN, JC ;
COPPOLA, DJ ;
RUPP, IP ;
SALLAN, SE ;
COHEN, HJ .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (09) :1780-1786
[5]  
ASSELIN BL, 1991, CANCER RES, V51, P6568
[6]   New evidence of hydroxylamine by creating quinoline-quinone-(5.8)-[8-oxy-quinolyl-5-imide]-(5), called "indo-oxin". [J].
Berg, R ;
Becker, E .
BERICHTE DER DEUTSCHEN CHEMISCHEN GESELLSCHAFT, 1940, 73 :172-173
[7]   Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations [J].
Boos, J ;
Werber, G ;
Ahlke, E ;
SchulzeWesthoff, P ;
NowakGottl, U ;
Wurthwein, G ;
Verspohl, EJ ;
Ritter, J ;
Jurgens, H .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (09) :1544-1550
[8]   L-ASPARAGINASE AND L-ASPARAGINE METABOLISM [J].
COONEY, DA ;
HANDSCHUMACHER, RE .
ANNUAL REVIEW OF PHARMACOLOGY, 1970, 10 :421-+
[9]  
DELLINGER CT, 1976, CANCER, V38, P1843, DOI 10.1002/1097-0142(197610)38:4<1843::AID-CNCR2820380463>3.0.CO
[10]  
2-J